[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"canser\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:canser":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100628250","clinical-study-of-68ga-dota-blp-pet-imaging-in-noninvasive-diagnosis-of-malignant-tumors-100628250",false,"NCT07459192","Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors","Inclusion Criteria:\n\n* Age over 18 years, gender not restricted;\n* patients with malignant tumors confirmed by biopsy or surgical pathology;\n* Imaging findings of suspicious lymph nodes or distant metastases;\n* informed consent signed in writing by the subject or his\u002Fher legal guardian.\n\nExclusion Criteria:\n\n* patients who have received antitumor therapy prior to PET\u002FCT or PET\u002FMR scanning;\n* Patients with severe medical conditions who cannot tolerate PET\u002FCT or PET\u002FMR scans;\n* The alternative subjects have contraindications to PET\u002FCT or PET\u002FMR scans;\n* exposure to radiation of more than 50 mSv in the past year;\n* The alternative subjects underwent major surgery within the past 3 months; received experimental drug or device therapy (with unclear efficacy or safety) within the past 1 month;\n* The alternative subjects had any clinical conditions that the principal investigator of this study considered to be potentially harmful or associated with the formulation.","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","OBSERVATIONAL","Immune checkpoint blockade (ICB) therapy has become a milestone breakthrough in oncology by activating the host immune system to recognize and eliminate tumor cells . Among these, programmed death protein 1 (PD-1) and its ligand (PD-L1) are currently the most widely used targets in clinical practice . However, clinical data indicate that only a subset of patients benefit from anti-PD-1\u002FPD-L1 therapy. Due to the heterogeneity of the tumor microenvironment and the spatiotemporal dynamic changes in PD-L1 expression, traditional tissue biopsy-based detection methods often fail to comprehensively assess disease status, leading to limited treatment response rates . Therefore, there is an urgent need to develop precise strategies for non-invasive, real-time, and dynamic evaluation of PD-L1 expression and treatment response.\n\nNuclear medicine molecular imaging techniques, particularly positron emission tomography (PET), provide a critical means for non-invasive in vivo visualization of tumor biomarkers . Given the pivotal role of PD-L1 in tumor immune evasion, real-time monitoring of its expression levels is of significant importance for the precise guidance of immunotherapy. In recent years, radiotracer agents based on peptides and small molecules have garnered considerable attention due to their advantages in tissue penetration, rapid blood clearance, and high signal-to-noise ratio imaging. Various PD-L1 probes (e.g., \\[¹⁸F\\]BMS-986229, \\[¹⁸F\\]AlF-NOTA-IMB) have demonstrated promising application potential in preclinical or clinical studies . Meanwhile, although PD-1\u002FPD-L1 monoclonal antibodies such as nivolumab and atezolizumab have significantly improved treatment outcomes for multiple tumors , they still exhibit inherent limitations in tissue penetration, in vivo clearance rate, imaging background, immunogenicity, and cost. Additionally, PD-L1-targeted therapies alone show limited efficacy in some patients, prompting researchers to further explore novel mechanisms such as protein degradation targeting (PROTAC) to achieve more comprehensive regulation of PD-L1.",[23],"Canser",[25,26,27,28],"canser","PET","DOTA-BLP","PD-L1","NOT_YET_RECRUITING","2026-03-04",{"date":32,"type":33},"2026-03-09","ACTUAL",{"date":35,"type":19},"2026-04-01",{"date":37,"type":19},"2027-12-31",{"name":39,"class":40},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100609280","benson-relaxation-exercises-and-sleep-quality-in-lung-cancer-patients-100609280","NCT07212517","Benson Relaxation Exercises and Sleep Quality in Lung Cancer Patients","The Effect of Benson Relaxation Exercises on Sleep Quality in Patients With Lung Cancer","Inclusion Criteria:\n\n* Patients aged 18 years and over,\n* Have been diagnosed with lung cancer and be receiving inpatient treatment,\n* Be conscious and able to communicate,\n* Agree to participate in breathing exercises during the study,\n* Score above 5 on the PSQI,\n* Sign a written informed consent form.\n\nExclusion Criteria:\n\n* Patients under 18 years of age,\n* Those with additional mental or cognitive disorders,\n* Those with physiological barriers to performing breathing exercises,\n* Those unable to complete the programme during the study period,\n* Those with a PSQI score above 5,\n* Those who violated the study protocol,\n\n  •. Those with an oxygen saturation value below 90,\n* Those scoring above 5 on the Visual Pain Scale,\n* Those who have previously practised yoga or meditation,\n* Patients with haemoptysis,\n* Patients taking any anxiolytic or hypnotic medication.\n\n  * During the 15 days of Benson relaxation exercise, patients in both the intervention and control groups will not be allowed to perform the exercise if their O2 saturation and pain level changes meet the exclusion criteria.","80 Years",{"count":51,"type":19},60,"INTERVENTIONAL",[54],"NA","The aim of this study is to investigate the effect of Benson Relaxation Exercises on sleep quality in hospitalized patients diagnosed with lung cancer. It is planned to be conducted as a randomized controlled trial.\n\nHypotheses of the Study H1: The sleep quality of lung cancer patients who undergo Benson relaxation exercises is statistically significantly better than that of patients who do not undergo such exercises.\n\nH2: There is no significant difference in sleep quality between patients who undergo Benson relaxation exercises and those who do not.",[57,58,23,59],"Sleep Quality","Relaxation","Benson Exercise",[61,62,63],"cancer patient","Benson relaxation","sleep Quality","2025-09-30",{"date":66,"type":33},"2025-10-08",{"date":64,"type":19},{"date":69,"type":19},"2026-07-15",{"name":71,"class":40},"Uskudar University"]